Back to search results

Observational Study of Lung Health in Young Adults

This observational study, part of the larger ALA Lung Health Cohort, aims to understand how your body, environment, and overall lung health are connected to the structure of your lung airways, blood vessels in your lungs and heart, and your lungs' ability to exchange gases. It involves 1000 healthy individuals aged 25-35. You would participate in four different lung function tests, including oscillometry (measuring air movement), slow vital capacity (SVC) and functional residual capacity (FRC) (measuring lung size), and diffusing capacity for carbon monoxide (DLCO) (measuring gas transfer). The study is looking for associations between these measurements and factors like airway-parenchymal dysanapsis (a mismatch in airway and lung tissue growth), vascular parenchymal dysanapsis (a mismatch in blood vessel and lung tissue growth), cardiac chamber size, and DLCO. This study is currently recruiting.

Study design
This is an observational study involving 1000 participants. It is not a treatment study, but rather aims to understand lung health.
What's involved
You would undergo four different lung function tests: oscillometry, slow vital capacity (SVC), functional residual capacity (FRC), and diffusing capacity for carbon monoxide (DLCO).
Compensation
Not stated in the trial record.
Follow-up
The primary endpoints are measured at Baseline, meaning at the start of your participation.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06177717

Deep Functional Phenotyping of the ALA Lung Health Cohort

Recruiting
Not specifiedAges 25–35Observational
Johns Hopkins University
~1,000 participants
Updated 2026-07-17 on ClinicalTrials.gov

At a glance

Recruiting sites
12 of 12 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Associations with airway-parenchymal dysanapsis
Measured over Baseline
+2 more outcomes measured

Conditions

Lung Diseases

Explore related trials

Healthy

Where it's being run

12 sites across 11 states
North Carolina2
Alabama1
California1
Colorado1
Florida1
Illinois1
Kansas1
Maryland1

Study leadership

  • Meredith McCormack, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins University

Who to contact

Meredith McCormack, MD
[email protected]
410-955-3467
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 25-35 years at the time of the baseline examination
Able to read and understand English or Spanish
Has a social security number
Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination.
Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant

Exclusion

Current (i.e. at the time of the visit) Global Initiative for Asthma (GINA) Step 4 or higher therapy (medium dose inhaled corticosteroid/long-acting beta agonist (ICS/LABA) or high dose inhaled corticosteroid \[ICS\] or add-on long-acting muscarinic antagonist (LAMA); Medium dose = \>250 fluticasone, propionate =100 fluticasone furoate, \>200 beclomethasone, \>400 budesonide, \>220 mometasone). The investigators will accept low-dose ICS/LABA or medium dose ICS.
3 or more unscheduled healthcare visits (provider/urgent care/ER) for asthma in the past 12 months OR
One asthma hospitalization in the past 12 months 2. History of any chronic lung disease other than asthma including but not limited to chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis, pulmonary hypertension 3. Current pregnancy 4. History of cancer other than non-melanoma skin cancer 5. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease) 6. Inability to comply with study procedures, including
Inability or unwillingness to provide informed consent
Inability to perform study measurements
Inability to be contacted by phone (via calls and/or text messaging) or email 7. Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit). 8. Institutionalization

What this trial measures

  • Associations with airway-parenchymal dysanapsisBaseline

    Correlation of adverse modifiable exposures and risk factors with increased airway-parenchymal dysanapsis

  • Associations with vascular parenchymal dysanapsis and cardiac chamber sizeBaseline

    Correlation of adverse modifiable exposures and risk factors with increased vascular parenchymal dysanapsis and increased cardiac chamber size

  • Associations with diffusing capacity for carbon monoxide (DLCO)Baseline

    Correlation of adverse modifiable exposures and risk factors with lower diffusing capacity for carbon monoxide (DLCO)